Resident leukocytes of the central nervous system, derived from yolk sac progenitors during embryonic development (E7-E8 in mice, week 4-6 in humans), migrating to brain before blood-brain barrier formation. Comprise 10-15% of total brain cells, serving as the CNS's primary innate immune system while performing critical homeostatic functions including synaptic pruning, debris clearance, neurotrophic support, and surveillance. Unlike peripheral macrophages, microglia are self-renewing and do not require replenishment from bone marrow under normal conditions.
Imagine microglia as the neighbourhood watch patrol of a gated community (the brain). During the day, they walk the streets continuously, checking that gardens are tidy, picking up litter, trimming overgrown hedges (synapses), and delivering food parcels to residents (BDNF, neurotrophic factors). They're in constant radio contact with the residents (neurons), getting updates on who needs help. Their patrol routes are efficient and systematic—every block gets checked multiple times per hour.
When there's a break-in (injury, infection, stroke), the patrol transforms. Some become aggressive responders (M1 phenotype)—they show up with sirens blaring, spray-painting warnings (TNF-α, IL-1β), setting up roadblocks, creating lots of noise and disruption. Others become cleanup and repair crews (M2 phenotype)—bringing construction supplies (IL-10, TGF-beta), hauling away debris (phagocytosis), and coordinating reconstruction efforts.
But here's the problem: if someone keeps calling 911 from outside the neighbourhood (chronic peripheral inflammation, stress, gut dysbiosis), the patrol stays in high-alert mode. They become paranoid (primed), overreact to minor issues, and eventually the constant emergency response damages the very houses they're supposed to protect. The patrol wears out, stops doing routine maintenance, and the entire neighbourhood deteriorates (neurodegeneration).
Embryonic Origin and Seeding:
Yolk sac primitive macrophages (E7.5 mice) → migrate to neural tube before BBB closure → express PU.1, IRF8, RUNX1 transcription factors → differentiate into microglia → self-renew via local proliferation (turnover rate ~28 days in rodents, ~4 years in humans)
Surveillance State (Resting Microglia):
Ramified morphology with highly motile processes (scan entire brain parenchyma every 4-5 hours) → express low levels of MHC II, CD45low, CD11b+, CX3CR1high → processes extend/retract continuously via actin polymerisation → contact synapses transiently (5-10 minutes) → detect ATP, fractalkine (CX3CL1), adenosine via purinergic receptors (P2Y12, P2Y6, A2A) → produce BDNF, IGF-1, NGF → support synaptic plasticity and neuronal survival
Activation Cascade (Classical/M1 Pathway):
graph TD
A["DAMPs/PAMPs: HMGB1, ATP, LPS"] --> B[TLR2/TLR4 activation]
B --> C[MyD88 adapter]
C --> D["NF-κB translocation"]
D --> E[Gene transcription]
E --> F[Pro-inflammatory cytokines]
F --> G1["TNF-α: TNFR signaling"]
F --> G2["IL-1β: IL-1R signaling"]
F --> G3["IL-6: IL-6R/gp130"]
G1 --> H[Neurotoxicity]
G2 --> H
G3 --> H
E --> I[iNOS expression]
I --> J[NO production]
J --> H
E --> K[NADPH oxidase]
K --> L[ROS production]
L --> H
Alternative Activation (M2 Pathway):
IL-4/IL-10/IL-13 → IL-4 receptor → STAT6 activation → gene expression → arginase-1 (competes with iNOS) → produces ornithine/polyamines → tissue repair → increased CD206, Ym1, Fizz1 expression → enhanced phagocytosis of debris → TGF-beta secretion → anti-inflammatory environment → supports remyelination and neurogenesis
Pattern Recognition:
Express Toll-like receptors (TLR1-9), NOD-Like Receptors (NLRP3, NLRC4), scavenger receptors (CD36, SR-A), complement receptors (CR3/CD11b) → detect DAMPs (HMGB1, heat shock proteins, extracellular ATP, DNA/RNA), PAMPs (LPS, peptidoglycan), protein aggregates (Aβ, α-synuclein) → phagocytosis via opsonization (C3b, antibodies) or direct recognition
Microglial Priming (Chronic Low-Grade Activation):
Repeated low-level stimulation → epigenetic modifications (H3K4me3 at inflammatory gene promoters) → enhanced response to subsequent stimuli → increased IL-1β, TNF-α baseline → reduced ramification → impaired phagocytic capacity → senescence markers (p16INK4a) → accumulation with aging → exaggerated neuroinflammatory response → contributes to cognitive decline
Synaptic Pruning Mechanism:
Complement tagging: neurons express C1q on weak/inactive synapses → C3b deposition → microglial CR3 receptors recognize C3b → engulf tagged synapses → critical during development (postnatal day 5-30 in rodents) and in disease states → excessive pruning in schizophrenia, Alzheimer's, chronic stress
Communication with Periphery:
Peripheral cytokines (IL-1β, TNF-α, IL-6) → cross blood-brain barrier at circumventricular organs → activate microglia → alternatively: vagus nerve afferents → nucleus tractus solitarius → norepinephrine release → microglial β2-adrenergic receptors → NF-κB activation → inflammatory gene transcription
Microglial dysfunction is central to virtually all neuroinflammatory, neurodegenerative, and neuropsychiatric conditions in cPNI practice:
Neurodegeneration:
- Alzheimer's Disease: microglia initially attempt to clear Aβ plaques but become overwhelmed → chronic M1 activation → produce inflammatory mediators that accelerate tau phosphorylation and neuronal death → microglial-derived IL-1β >5 pg/mL correlates with cognitive decline
- Parkinson's Disease: α-synuclein aggregates activate microglia via TLR2 → chronic ROS production → dopaminergic neuron loss in substantia nigra
- Multiple Sclerosis: microglial activation precedes demyelination → produce TNF-α (oligodendrocyte toxicity), glutamate (excitotoxicity), reactive nitrogen species → phagocytose myelin debris but also healthy myelin in active lesions
Psychiatric Disorders:
- Depression: elevated peripheral inflammation (CRP >3 mg/L, IL-6 >2 pg/mL) activates microglia → IDO expression → shunts tryptophan to kynurenine pathway → quinolinic acid (NMDA agonist, neurotoxic) instead of serotonin → explains ~30% of treatment-resistant depression
- Anxiety: microglial activation in amygdala and prefrontal cortex correlates with threat sensitivity → excessive synaptic pruning reduces inhibitory control
- Autism: prenatal immune activation (maternal IL-6, IL-17) → persistent microglial priming → altered synaptic development and pruning patterns
Chronic Pain:
Peripheral nerve injury → spinal cord microglia activation within 24-48h → express P2X4 receptors → ATP release from damaged neurons → P2X4 stimulation → BDNF release → downregulates KCC2 (chloride transporter) in dorsal horn neurons → disinhibition → central sensitization → mechanical allodynia → chronic neuropathic pain states
Metabolic Conditions:
Hypothalamic inflammation in obesity/Type 2 Diabetes → microglial activation in arcuate nucleus → impaired leptin/insulin signalling → disrupted energy balance → contributes to metabolic syndrome
cPNI Intervention Strategy:
The five systems model applies directly: peripheral inflammation from gut dysbiosis, chronic stress, metabolic dysfunction, or infectious disease relentlessly activates microglia through barrier crossing and vagal signaling. Priority interventions:
- Reduce peripheral inflammation: restore gut barrier function, address SIBO/dysbiosis, optimize omega-3 index (target >8% reduces microglial activation markers)
- Omega-3 supplementation: DHA preferentially incorporates into microglial membranes → reduces TLR4 signaling → shifts toward M2 phenotype → increases specialized pro-resolving mediators production (target: 2-4g EPA+DHA daily)
- Sleep optimization: microglial processes expand during sleep to clear metabolic waste via glymphatic system → sleep deprivation sustains M1 activation
- Stress management: chronic cortisol primes microglia → HPA axis dysregulation perpetuates neuroinflammation
- Metabolic flexibility: ketones (beta-hydroxybutyrate) reduce NLRP3 inflammasome activation in microglia
- Polyphenols: curcumin, resveratrol, EGCG inhibit microglial NF-κB signaling
- Exercise: BDNF release shifts microglia toward neuroprotective phenotype
Evolutionary Mismatch:
Microglia evolved for acute threat response (infection, injury) with resolution. Modern chronic low-grade systemic inflammation from diet, sedentary behavior, chronic stress, and pollution constitutes a novel evolutionary pressure—microglia remain in prolonged activation, exhausting their repair capacity and accelerating brain aging.
- Embryonic origin: yolk sac E7-E8, not bone marrow—explains why they're distinct from all other tissue macrophages
- Turnover time: ~28 days in rodents, ~4.2 years in humans (radioisotope dating studies)
- Proportion: comprise 5-12% of cells in grey matter, up to 16% in hippocampus, fewer in white matter (~0.5%)
- Process motility: microglial processes extend/retract at ~1.5 μm/min, surveying ~15,000 synapses per cell daily
- Activation timeline: detectable morphological changes within 1-2h of injury, peak inflammatory mediator production 24-48h, resolution 7-14 days (if stimulus removed)
- M1 markers: iNOS, CD86, CD16/32, IL-1β, TNF-α, IL-6, MHCII high
- M2 markers: Arginase-1, CD206, Ym1, IL-10, TGF-beta, CD163
- Priming threshold: systemic LPS challenge as low as 0.5 mg/kg induces measurable microglial sensitization
- Aging effect: microglial density increases 10-20% with age, baseline inflammatory cytokine expression doubles, phagocytic efficiency decreases 40-50%
- Sex differences: female microglia more reactive to inflammatory stimuli (estrogen receptor-mediated), males have higher baseline complement expression
- ATP sensing: P2Y12 receptor detects ATP gradients down to nanomolar concentrations over distances >50 μm
- neuroinflammation — microglia are the primary cellular mediators of CNS inflammatory responses, producing the majority of brain-derived inflammatory cytokines
- blood-brain barrier — peripheral inflammatory signals cross BBB at circumventricular organs or during barrier disruption to activate microglia
- cytokines — microglia both produce (IL-1β, TNF-α, IL-6) and respond to cytokines through extensive receptor expression, creating positive feedback loops
- synaptic pruning — microglia eliminate excess or weak synapses during development and disease via complement-mediated recognition and phagocytosis
- neurodegeneration — chronic microglial activation drives progressive neuronal loss in Alzheimer's, Parkinson's, ALS through inflammatory mediator production
- Depression — microglial IDO activation shunts tryptophan to quinolinic acid instead of serotonin, contributing to inflammation-associated depression
- chronic pain — spinal cord microglial activation within 24h of nerve injury releases BDNF, causing central sensitization and allodynia
- BDNF — produced by surveilling microglia to support neuronal health; reduced in primed/activated states
- Alzheimer's Disease — microglia attempt Aβ clearance but become chronically activated, accelerating tau pathology and neuronal death
- gut-brain axis — gut dysbiosis drives systemic inflammation that activates microglia via cytokine crossing or vagal afferent signaling
- vagus nerve — peripheral immune signals transmitted via vagal afferents to NTS trigger norepinephrine release, activating microglial β2-adrenergic receptors
- stress — chronic glucocorticoid exposure primes microglia through epigenetic modifications, enhancing inflammatory responses
- sleep — microglial processes expand during sleep to facilitate glymphatic clearance; sleep deprivation sustains M1 activation
- Omega-3 — DHA incorporation into microglial membranes reduces TLR4 signaling and promotes M2 polarization and SPM production
- complement receptors — CR3 (CD11b) recognizes C3b-tagged synapses for pruning; dysregulated in schizophrenia and autism
- TLR4 — primary pattern recognition receptor detecting LPS and DAMPs, initiating NF-κB-driven inflammatory gene transcription
- NLRP3 inflammasome — activated in microglia by diverse signals (ATP, Aβ, crystals), cleaves pro-IL-1β to active IL-1β
- astrocytes — bidirectional communication with microglia; activated astrocytes produce CCL2 recruiting microglia, microglia produce IL-1α activating astrocytes
- Multiple Sclerosis — microglial activation precedes demyelination; produce TNF-α damaging oligodendrocytes and excessive ROS
- Parkinson's Disease — α-synuclein aggregates activate microglia via TLR2, driving chronic dopaminergic neuron loss in substantia nigra
- Autism — prenatal immune activation causes persistent microglial priming, altering developmental synaptic pruning patterns
- hypothalamus — hypothalamic microglial activation in obesity/diabetes impairs leptin/insulin signaling, contributing to metabolic dysfunction
- tumor necrosis factor — key microglial-derived cytokine causing neuronal apoptosis, blood-brain barrier disruption, and oligodendrocyte death
- IL-1β — cleaved from pro-IL-1β by caspase-1 in activated microglia; drives fever, sickness behavior, and amplifies neuroinflammatory cascades
- IL-6 — produced by activated microglia; crosses BBB to affect peripheral immunity and HPA axis; >10 pg/mL associated with cognitive impairment